Previous 10 | Next 10 |
- Integrated analysis confirms statistically superior efficacy and safety of voclosporin in combination with MMF and steroids over standard-of-care – - Voclosporin pharmacokinetic data supports consistent dose-response, potentially eliminating the need for therapeutic d...
Aurinia’s voclosporin demonstrated exceptional Phase 3 trial results to treat Lupus Nephritis “LN”, a significant unmet medical need with blockbuster potential. Voclosporin’s PDUFA date is in January 2021 and Aurinia is prepared to commercialize the drug on...
Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company aiming to develop and commercialize therapies for Lupus Nephritis ("LN") and Dry Eye Syndrome ("DES"). Aurinia's LN therapeutic Voclosporin has completed Phase 3 and is awaiting NDA results at the PDUFA target ...
Aurinia Pharmaceuticals (AUPH) announces Time Is Nephrons, the first-ever lupus nephritis ((LN)) disease-state awareness campaign for healthcare professionals.The initiative aims to highlight the importance of active screening for early diagnosis to minimize the impact on kidney function...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced Time Is Nephrons, the first-ever lupus nephritis (LN) disease-state awareness campaign for healthcare professionals (HCPs). The initiative aims to highlight the ...
- Voclosporin ophthalmic solution (VOS) results on track to be reported in the fourth quarter of 2020 - - Study builds on positive head-to-head data with approved treatment reported in prior Phase 2a study - - Dry eye syndrome is a chronic autoimmune disorder affecting...
The following slide deck was published by Aurinia Pharmaceuticals Inc. in conjunction with this Read more ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in fireside chats during the following upcoming virtual investor conferences: H.C. Wainwright & Co. 22 nd Annual Global I...
The Dry Eye Syndrome is a relatively common disease whose prevalence increases as people age. It is believed that more than 6% of the population over age of 40 and 15% of the population over age of 65 is impacted by DES in US, with symptoms that vary from mild (redness, irritation, etc.) to se...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company’s Compensation Committee granted 105...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...